← brief for 2026-10-20 · Slowing decline

Oral Semaglutide and the Kidney: Promise, Limitations, and the Road Ahead.

Letter No results yet Not peer reviewed

Key takeaways

This is a letter to the editor about a weight-loss drug called semaglutide. It discusses the promise and limits of using this drug for kidney disease. There are no new clinical results in this letter.

Who did this work

Ma W · Xia F · Tao D

Source

Letter · PubMed, the drug frontier · 2026 Nov 1
https://pubmed.ncbi.nlm.nih.gov/42900811/